Application 021731

Type
NDA
Sponsor
TOLMAR THERAP

Related Records

Application Products

ProductDrugIngredientFormStrengthReference drugReference standard
001ELIGARDLEUPROLIDE ACETATEINJECTABLE;SUBCUTANEOUS45MG/VIALYesYes

NDC Listings For This Application

NDCNameNonproprietary nameLabelerMarketing categoryStatus
62935-452ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent
62935-453ELIGARDLeuprolide AcetateTOLMAR PHARMACEUTICALS INC.NDACurrent

Documents

DocumentSubmission typeDate
85890SUPPL 2026-05-12
85855SUPPL 2026-05-08
81372SUPPL 2025-02-25
81347SUPPL 2025-02-25
81016SUPPL 2025-02-06
80966SUPPL 2025-02-06
78533SUPPL 2024-05-22
78532SUPPL 2024-05-22
77296SUPPL 2024-01-25
77288SUPPL 2024-01-24
74864SUPPL 2023-07-21
74863SUPPL 2023-07-21
74857SUPPL 2023-07-21
74855SUPPL 2023-07-21
72745SUPPL2022-11-29
57734SUPPL2019-02-21
57697SUPPL2019-02-19
37552SUPPL2016-03-03
6079SUPPL2016-03-02
37551SUPPL2014-10-15
6078SUPPL2014-10-14
37550SUPPL2013-03-01
28490SUPPL2013-03-01
23674ORIG2011-12-20
37549SUPPL2011-04-11
28489SUPPL2011-04-11
16276SUPPL2011-01-20
6077SUPPL2011-01-20
28488SUPPL2010-10-13
37548SUPPL2010-10-12
6076SUPPL2007-11-19
16275SUPPL2007-11-13
28487SUPPL2006-10-05
21796ORIG2006-09-27